- Home
- PHGE vs TXMD Comparison
PHGE vs TXMD Comparison
Compare PHGE & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHGE
- TXMD
- Stock Information
- Founded
- PHGE 2015
- TXMD 2008
- Country
- PHGE Israel
- TXMD United States
- Employees
- PHGE N/A
- TXMD N/A
- Industry
- PHGE Biotechnology: Pharmaceutical Preparations
- TXMD Biotechnology: Pharmaceutical Preparations
- Sector
- PHGE Health Care
- TXMD Health Care
- Exchange
- PHGE Nasdaq
- TXMD Nasdaq
- Market Cap
- PHGE 13.3M
- TXMD 12.8M
- IPO Year
- PHGE N/A
- TXMD N/A
- Fundamental
- Price
- PHGE $0.96
- TXMD $1.30
- Analyst Decision
- PHGE Strong Buy
- TXMD
- Analyst Count
- PHGE 2
- TXMD 0
- Target Price
- PHGE $13.50
- TXMD N/A
- AVG Volume (30 Days)
- PHGE 48.8K
- TXMD 738.0K
- Earning Date
- PHGE 04-02-2025
- TXMD 03-28-2025
- Dividend Yield
- PHGE N/A
- TXMD N/A
- EPS Growth
- PHGE N/A
- TXMD N/A
- EPS
- PHGE N/A
- TXMD N/A
- Revenue
- PHGE N/A
- TXMD $1,596,000.00
- Revenue This Year
- PHGE N/A
- TXMD $605.07
- Revenue Next Year
- PHGE N/A
- TXMD $1.11
- P/E Ratio
- PHGE N/A
- TXMD N/A
- Revenue Growth
- PHGE N/A
- TXMD N/A
- 52 Week Low
- PHGE $0.48
- TXMD $0.70
- 52 Week High
- PHGE $8.55
- TXMD $2.75
- Technical
- Relative Strength Index (RSI)
- PHGE 65.22
- TXMD 68.51
- Support Level
- PHGE $0.87
- TXMD $0.95
- Resistance Level
- PHGE $0.99
- TXMD $1.08
- Average True Range (ATR)
- PHGE 0.08
- TXMD 0.09
- MACD
- PHGE 0.01
- TXMD 0.02
- Stochastic Oscillator
- PHGE 89.20
- TXMD 49.30
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.